冠心病患者治疗前后血小板膜糖蛋白GPⅡb/Ⅲa、血栓素B_2的变化  

CHANGES OF PLATELET MEMBRANE GLYCOPROTEIN Ⅱb/Ⅲa EXPRESSION AND PLASMA THROMBOXANE B_2 LEVELS IN PATIENTS WITH CORONARY HEART DISEASE BEFORE AND AFTER TREATMENT

作　　者：陈世德[1] 伍伟锋[1] 刘唐威[1] 秦雪[2] 

机构地区：[1]广西医科大学第一附属医院心内科,南宁530021 [2]广西医科大学第一附属医院临床医学实验部

出　　处：《广西医科大学学报》2010年第2期242-244,共3页Journal of Guangxi Medical University

基　　金：广西科学基金资助项目(桂科青0447031);教育部"春晖计划"基金资助项目(Z2005-1-45001)

摘　　要：目的:观察冠心病(CHD)患者治疗前后血小板膜糖蛋白(GPⅡb/Ⅲa)表达和血浆血栓素B2(TXB2)水平的变化,探讨其临床意义。方法:分别采用流式细胞术(FCM)、酶联免疫吸附法(ELISA)检测60例CHD患者(CHD组)接受阿司匹林(100mg/d)治疗前、治疗2周后及20名健康体检者(正常对照组)的血小板膜糖蛋白GPⅡb/Ⅲa表达阳性率、血浆TXB2水平。结果:治疗后,CHD患者血小板膜糖蛋白GPⅡb/Ⅲa表达阳性率、血浆TXB2水平均比治疗前明显降低(P<0.01),但仍高于正常对照组(P<0.01)。结论:阿司匹林可在一定程度上抑制CHD患者血小板活化与聚集。Objective：To investigate the changes of platelet membrane glycoprotein Ⅱb/Ⅲa （GPⅡb/Ⅲa） expression and plasma thromboxane B2 （TXB2） levels in patients with coronary heart disease （CHD） before and after 2 weeks aspirin treatment, and to explore its clinical significance. Methods：Before treatment, the GP Ⅱb/Ⅲa-positive platelets and plasma TXB2 levels were detected in 60 patients with CHD and in 20 normal controls by flow cytometry（FCM）and enzyme-linked immunosorbent assay （ELISA）,respectively. After treatment of aspirin（100 mg/d）for 2 weeks in CHD patients, the GP Ⅱb/Ⅲa-positive platelets and plasma TXB2 levels in patients were detected by FCM and ELISA again. Results：The numbers of GP Ⅱb/Ⅲa- positive platelets and the levels of plasma TXB2 in patients with CHD were significantly declined after aspirin treatment （ P 〈0.01）, but still higher than those in normal controls（ P 〈0.01）. Conclusion： Aspirin may inhibit platelet activation and aggregation in patients with CHD.

关 键 词：冠状动脉疾病 阿司匹林 血小板膜糖蛋白 血栓素B2 

分 类 号：R541.4[医药卫生—心血管疾病]